Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Guardant Health Inc (GH)

Guardant Health Inc (GH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,502,503
  • Shares Outstanding, K 102,220
  • Annual Sales, $ 373,650 K
  • Annual Income, $ -405,670 K
  • 60-Month Beta 0.80
  • Price/Sales 14.70
  • Price/Cash Flow N/A
  • Price/Book 17.21
Trade GH with:

Options Overview Details

View History
  • Implied Volatility 109.53% ( -1.09%)
  • Historical Volatility 70.53%
  • IV Percentile 98%
  • IV Rank 86.84%
  • IV High 119.73% on 05/05/22
  • IV Low 42.19% on 11/11/21
  • Put/Call Vol Ratio 0.66
  • Today's Volume 1,928
  • Volume Avg (30-Day) 2,019
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 73,868
  • Open Int (30-Day) 70,551

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.44
  • Number of Estimates 7
  • High Estimate -1.04
  • Low Estimate -2.30
  • Prior Year -1.06
  • Growth Rate Est. (year over year) -35.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.86 +14.87%
on 09/01/22
61.67 -12.71%
on 09/12/22
+5.61 (+11.63%)
since 08/30/22
3-Month
40.37 +33.34%
on 07/01/22
61.67 -12.71%
on 09/12/22
+13.49 (+33.44%)
since 06/30/22
52-Week
27.65 +94.68%
on 05/12/22
121.26 -55.61%
on 11/01/21
-71.18 (-56.94%)
since 09/30/21

Most Recent Stories

More News
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights...

GH : 53.83 (+0.20%)
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 European Society for Medical Oncology...

GH : 53.83 (+0.20%)
Why Guardant Health Crushed the Market Today

The company deepened its relationship with an important peer.

GH : 53.83 (+0.20%)
MRK : 86.12 (-0.60%)
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating...

GH : 53.83 (+0.20%)
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York....

GH : 53.83 (+0.20%)
2 Stocks Leading the Market Rebound

Can these companies' recent (short) run last?

ADYEY : 12.5200 (+3.73%)
GH : 53.83 (+0.20%)
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers

Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Guardant Reveal™, the only tissue-free test for the detection of residual and recurrent disease for colorectal...

GH : 53.83 (+0.20%)
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360 ® CDx liquid biopsy test as a companion...

GH : 53.83 (+0.20%)
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point,...

GH : 53.83 (+0.20%)
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X...

GH : 53.83 (+0.20%)
BPMC : 65.89 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

3rd Resistance Point 58.56
2nd Resistance Point 57.32
1st Resistance Point 55.58
Last Price 53.83
1st Support Level 52.59
2nd Support Level 51.35
3rd Support Level 49.60

See More

52-Week High 121.26
Fibonacci 61.8% 85.50
Fibonacci 50% 74.46
Fibonacci 38.2% 63.41
Last Price 53.83
52-Week Low 27.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar